Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript

Scott Wolchko: Yes. I mean we are going to work with the investigators on the study. I think there is €“ I think there is desire for on the part of these investigators to complete the study and potentially publish the results. I think as Ed alluded to, we did make the decision to keep following patients in the 516 and 596 studies, because we do have patients that are continuing in response. And so yes, I do think we internally at Fate are not going to prioritize, essentially the 516 and 596 sort of data windup and then presentation, but we will absolutely work with investigators to enable that. I think it’s €“ I think we will wait until all patients have reached the 1 year follow-up since we have committed to follow patients for 1 year to get a sense of durability response.

Operator: Thank you. I am not showing any further questions at this time. I will turn the call back over to Scott Wolchko for any closing remarks.

Scott Wolchko: Thank you all for your participation in today’s call. Do well.

Operator: Ladies and gentlemen, this does conclude today’s presentation. You may now disconnect and have a wonderful day.